Inhalable nanoliposomes target senescence and overcome chemoresistance in mouse lung cancer
The formulation co-delivers rapamycin and doxorubicin across the mucus barrier to inhibit mTOR and suppress tumor growth without evident systemic toxicity.
Biomaterials · Man Y et al. · Paper published 23 Sep 2026
In a chemoresistant lung cancer mouse model, researchers tested an inhalable nanoliposome system engineered to traverse the pulmonary mucus barrier and target senescent cancer cells. The lipid nanoparticles incorporated an aptamer targeting L1 cell adhesion molecule (L1CAM) to co-deliver rapamycin and doxorubicin directly to tumor sites. Upon inhalation, the formulation selectively accumulated in senescent lung cancer cells overexpressing L1CAM. Inside tumors, rapamycin inhibited the mTOR pathway, which reversed the senescent phenotype, hyperactivated autophagy, blocked senescence propagation, and enhanced drug retention. This molecular shift resensitized the cancer cells to chemotherapy. Inhalation of the nanoliposomes significantly suppressed tumor growth in the mice without causing appreciable systemic toxicity.
Why it matters
Therapy-induced senescence can propagate and drive acquired resistance to DNA-damaging treatments. Targeting and pharmacologically reversing this senescent phenotype via mTOR inhibition provides a way to disrupt senescence-driven pathology directly in diseased tissue.
Caveats
The findings are restricted to a chemoresistant mouse model, and the formulation has not yet been tested in human clinical trials.
Written from the paper’s abstract, and every claim checked against it before publishing. Read the paper for the full methods and data.
The paper
Inhalable mucus-penetrating and senescence-targeted nanoliposomes reverse senescence to overcome chemoresistance for enhanced lung cancer therapy
Man Y, Liu Y, Liu Y et al.
Biomaterials · 23 Sep 2026 · Peer-reviewed
- Relevance
- Relevant
- News value
- Notable
- Evidence
- Animals
- Status
- Peer-reviewed
More on Cellular senescence
See allDasatinib and quercetin reduce liver fibrosis in a phase-2 MASH trial
The senolytic combination improved liver fibrosis without disease worsening in nearly half of treated participants while lowering cellular senescence markers.
Nature metabolism · Koning M et al.
A distinct p21-driven macrophage senotype accumulates during aging and liver disease
Researchers identified a p53-p21-Cyclin D2 axis that governs senescent macrophages in mice and human liver cirrhosis and can be cleared with senolytics.
bioRxiv · Torres G et al.
DNA methylation proxies of senescence markers track human disease and mortality
The new blood-based tools estimate senescence gene activity to predict incident diseases, all-cause mortality, and clinical treatment responses.
medRxiv · Simpson DJ et al.
Bispecific T cell engager eliminates senescent cells in mice and nonhuman primates
Monitored by serum transaminase levels, low doses of the drug alleviated age-related pathologies without causing the hepatotoxicity seen at higher doses.
Aging cell · Deng J et al.
A deep learning score for cellular senescence predicts human mortality and disease risk
The proteomic biomarker tracked chronic illness risk in the UK Biobank and shifted following an 18-month multimodal exercise intervention.
Aging cell · Zhao S et al.